Douglas Sipp
Douglas Sipp
RIKEN Center for Biosystems Dynamics Research
Email yang diverifikasi di
JudulDikutip olehTahun
Monitoring and regulating offshore stem cell clinics
S Kiatpongsan, D Sipp
Science 323 (5921), 1564-1565, 2009
Setting global standards for stem cell research and clinical translation: the 2016 ISSCR guidelines
GQ Daley, I Hyun, JF Apperley, RA Barker, N Benvenisty, AL Bredenoord, ...
Stem cell reports 6 (6), 787-797, 2016
Consensus guidance for banking and supply of human embryonic stem cell lines for research purposes
International Stem Cell Banking Initiative
Stem Cell Reviews and Reports 5 (4), 301-314, 2009
Tissue interactions in neural crest cell development and disease
Y Takahashi, D Sipp, H Enomoto
Science 341 (6148), 860-863, 2013
Clear up this stem-cell mess
D Sipp, PG Robey, L Turner
Nature 561 (7724), 455-457, 2018
Marketing of unproven stem cell–based interventions: A call to action
D Sipp, T Caulfield, J Kaye, J Barfoot, C Blackburn, S Chan, M De Luca, ...
Science translational medicine 9 (397), eaag0426, 2017
Global distribution of businesses marketing stem cell-based interventions
I Berger, A Ahmad, A Bansal, T Kapoor, D Sipp, JEJ Rasko
Cell stem cell 19 (2), 158-162, 2016
Confronting stem cell hype
T Caulfield, D Sipp, CE Murry, GQ Daley, J Kimmelman
Science 352 (6287), 776-777, 2016
Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI)
PW Andrews, D Baker, N Benvinisty, B Miranda, K Bruce, O Brüstle, ...
Regenerative medicine 10 (2s), 1-44, 2015
Regulation: sell help not hope
P Bianco, D Sipp
Nature 510 (7505), 336-337, 2014
Patients beware: commercialized stem cell treatments on the web
PL Taylor, RA Barker, KG Blume, E Cattaneo, A Colman, H Deng, ...
Cell Stem Cell 7 (1), 43-49, 2010
US regulation of stem cells as medical products
D Sipp, L Turner
Science 338 (6112), 1296-1297, 2012
Conditional approval: Japan lowers the bar for regenerative medicine products
D Sipp
Cell Stem Cell 16 (4), 353-356, 2015
The unregulated commercialization of stem cell treatments: a global perspective
D Sipp
Frontiers of medicine 5 (4), 348-355, 2011
Policy: global standards for stem-cell research
J Kimmelman, I Hyun, N Benvenisty, T Caulfield, HE Heslop, CE Murry, ...
Nature 533 (7603), 311-313, 2016
Offshore stem cell treatments
S Kiatpongsan, D Sipp
Nature Reports Stem Cells, 2008
New ISSCR guidelines: clinical translation of stem cell research
J Kimmelman, HE Heslop, J Sugarman, L Studer, N Benvenisty, ...
The Lancet 387 (10032), 1979-1981, 2016
Oversight for clinical uses of autologous adult stem cells: lessons from international regulations
T Lysaght, I Kerridge, D Sipp, G Porter, BJ Capps
Cell Stem Cell 13 (6), 647-651, 2013
Pay-to-participate funding schemes in human cell and tissue clinical studies
D Sipp
Regenerative medicine 7 (6s), 105-111, 2012
Enabling consistency in pluripotent stem cell-derived products for research and development and clinical applications through material standards.
BDA French A, Bravery C, Smith J, Chandra A, Archibald P, Gold JD, Artzi N ...
Stem Cells Translational Medicine 4 (3), 217-223, 2015
Sistem tidak dapat melakukan operasi ini. Coba lagi nanti.
Artikel 1–20